抗P-170单克隆抗体MRK-16对膀胱癌多药耐受的诊断及调节作用

The diagnostic and modulating effect of anti P-170 monoclonal antibody MRK-16 on the MDR human bladder cancer

本文通过抗P-170单克隆抗体免疫组化研究发现,不同诱导途径建立的人膀胱癌多药耐受(MDR)。细胞均表达P-170,说明P-170在人类膀胱癌MDR机制中起重要的中介作用,MRK-16对不同类型的人膀胱癌MDR均有特异性诊断价值。MRK-16具有明显的化疗增敏作用,不仅能明显提高膀胱癌MDR细胞的化疗效果,而且能轻度提高敏感细胞的化疗疗效,其增效作用具有剂量依赖性,并与细胞本身的耐药水平相关,说明MRK-16对人膀胱癌化疗具有明显的调节增敏作用。

The immunochemohistologic study by using anti-P-170 monoclonal antibody in this assay showed: The P-170 glycoprotein was over expressed in all human bladder carcinoma MDR cell lines developed by different inductives methods, indicating that MRK-16 may play an important mediated role in the mechanisms of bladder cancer MDR, and is very valuable for the specific diagnosis of various types of human MDR bladder carcinoma. The drug-sensitive test of combination of MRK-16 and cytotoxic drugs showed: MRK-16 had a significant effect to increase the sensitivity in the chemotherapy of bladder cancer. It can not only elevate the chemotherapeutic effect on the MDR bladder cancer cells, but also elevate the chemotherapeutic effect on the sensitive cells slightly. The elevate effects were doge dependent , and were relavant to the level of drug resistance. This indicated that MRK-16 had a significant effect to reversing MDR on the chemotherapy of all human bladder cancer.